Adial Pharmaceuticals (ADIL) Earnings Analysis

Adial Pharmaceuticals (ADIL) next reports earnings on 2026-08-12, consensus EPS -1.01667 USD. Last quarter (2026-03-10) it beat with EPS -1.81 USD vs -2.1 USD est (+13.8%). It has beaten estimates in 5/5 recent quarters (100%). Trailing P/E -0.28.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ADIL next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-1.01667 USD
Revenue estimaten/a

ADIL earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-10-1.81 USD-2.1 USD+13.8%Beat
2025-11-13-2 USD-2.25 USD+11.1%Beat
2025-08-13-0.18 USD-0.22 USD+18.2%Beat
2025-05-14-0.34 USD-0.5 USD+32%Beat
2025-03-04-0.15 USD-0.38 USD+60.5%Beat

Beat rate: 5/5 (100%) over reported quarters with consensus data.

ADIL valuation and analyst view

Trailing P/E-0.28
Trailing EPS-5.67164 USD
Price / book1.00
Dividend yield0.00%
Market cap0.00B
Analyst consensusBuy (3 buy / 0 hold / 0 sell)
Avg price target6 USD

Related research pages

Frequently asked questions

When is Adial Pharmaceuticals (ADIL)'s next earnings date?

Adial Pharmaceuticals is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -1.01667 USD.

Did ADIL beat earnings last quarter?

In its 2026-03-10 report, ADIL posted EPS of -1.81 USD versus a -2.1 USD estimate — a beat of 13.8%.

What is ADIL's earnings track record?

Over the last 5 reported quarters with consensus data, ADIL beat estimates 5 times (100%).

What is ADIL's current P/E ratio and EPS?

ADIL trades at a trailing P/E of -0.28 on trailing EPS of -5.671637803999536 USD.

What do analysts rate ADIL?

Analyst consensus is "Buy" across 3 ratings (0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 6 USD.